BLCO Stock Chart & Stats
C$22.72
C$0.30(1.32%)
At close: 4:00 PM EDT
C$22.72
C$0.30(1.32%)
Day’s Range― - ―
52-Week RangeC$18.25 - C$25.70
Previous CloseN/A
Volume101.00
Average Volume (3M)2.16K
Market Cap
C$8.47B
Enterprise ValueC$10.72K
Total Cash (Recent Filing)C$367.00M
Total Debt (Recent Filing)C$43.00M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 04, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding357,165,250
10 Day Avg. Volume2,923
30 Day Avg. Volume2,157
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)0.94
Price to Sales (P/S)1.18
P/FCF Ratio-91.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$27.71Price Target Upside21.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.13
Revenue Forecast (FY)C$7.71B
Bulls Say, Bears Say
Bulls Say
Broad-based Revenue Growth Across SegmentsSustained, multi-segment revenue growth indicates diversified end markets and reduces reliance on any single product line. Durable demand across Pharmaceuticals, Surgical and Vision Care supports steady cash flows and resilience to localized shocks or competitive pressures over the next 2–6 months.
Improving Cash Generation And DeleveragingMaterial improvement in operating cash flow and a swing to positive free cash flow indicate better internal funding capacity. Continued deleveraging (one turn reduction year-over-year) improves financial flexibility, lowering refinancing risk and supporting capex, R&D and strategic initiatives sustainably.
Sustained R&D Spend While Expanding MarginsMaintaining elevated R&D intensity alongside margin expansion reflects disciplined portfolio investment and operational efficiency. This balance supports long-term product pipeline development and differentiation (pharma and surgical), enhancing durable competitive advantages and future revenue quality.
Bears Say
Elevated Leverage And Interest BurdenHigh net leverage and sizeable interest costs constrain earnings retention and limit strategic optionality. Interest expense materially reduces free cash available for reinvestment or M&A, making the company more sensitive to rate moves and refinancing conditions over a multi-quarter horizon.
Key Pipeline And Regulatory Milestones PendingSignificant near-term clinical readouts and regulatory submissions create binary execution risk. Outcomes will materially affect future growth trajectories and product-level profitability; delays or negative results could derail expected revenue ramp and investor confidence for several quarters.
Profitability Still Impaired; Negative ReturnsPersistent net losses and negative ROE indicate the company has yet to consistently convert strong revenue and gross margins into sustainable bottom‑line profitability. Until operating leverage and non-operating costs normalize, earnings-generation capacity and capital allocation will remain constrained.
Bausch + Lomb Corporation News
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was C$18.25 and its highest was C$25.70 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Bausch + Lomb Corporation’s market cap is C$8.47B.
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Nov 04, 2026 which is in 91 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Jul 29, 2026. The company reported C$0.211 earnings per share for the quarter, missing the consensus estimate of C$0.216 by -C$0.006.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is 0.29.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 357,165,250 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of C$0.211 in its last earnings report, missing expectations of C$0.216. Following the earnings report the stock price went down -2.394%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Currently, no hedge funds are holding shares in TSE:BLCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch + Lomb Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$27.71 (21.98% Upside)
C$27.71 (21.98% Upside)
Blogger Sentiment
Bullish
TSE:BLCO Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.20%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
BLCO Company Deck
BLCO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum across revenue, margin expansion, cash generation and deleveraging. Broad-based growth across segments (Pharmaceuticals, Surgical, Vision Care), robust adjusted EBITDA growth, raised guidance and continued R&D investment were emphasized as evidence that the three-year plan is on track. Notable risks include elevated leverage and interest expense, macro/currency sensitivity (consumer demand tied to gas prices), ongoing regional disruptions (e.g., strikes), competitive dynamics in surgical and dry eye markets, and several important clinical and regulatory milestones still pending. Overall, the positives in growth, margins, cash flow and guidance upgrades substantially outweigh the outlined risks.View all TSE:BLCO earnings summariesBLCO Stock 12 Month Forecast
Average Price Target
C$27.71
▲(21.98% Upside)